论文部分内容阅读
选取新诊断的2型糖尿病患者60例,应用重和林M30进行治疗12周,对比治疗前后患者空腹血糖、餐后2h血糖、睡前血糖、血脂、胰岛素用量、体重等指标,同时记录治疗过程中出现低血糖反应发生情况。结果:治疗12周后空腹血糖(FPG)、餐后2小时血糖(2h PG)、睡前血糖、血脂的较治疗前明显下降,差异有统计学意义(P<0.05),体重指数较治疗前比较差异无统计学意义(P>0.05),无严重低血糖反应发生。结论:重和林M30治疗新诊断的2型糖尿病患者,可显著降低血糖、血脂水平,低血糖发生率低,无体重增加,安全性好,部分患者可逐渐停用胰岛素。
Sixty patients with newly diagnosed type 2 diabetes mellitus were selected and treated with Chonghelin M30 for 12 weeks. The fasting blood glucose, postprandial blood glucose 2h, blood glucose before going to sleep, blood lipids, insulin dosage and body weight were compared before and after treatment. In the occurrence of hypoglycemia reaction. Results: After 12 weeks of treatment, fasting blood glucose (FPG), 2h postprandial blood glucose (2h PG), pregrowth blood glucose and lipids decreased significantly compared with those before treatment (P <0.05). The body mass index The difference was not statistically significant (P> 0.05), no serious hypoglycemia occurred. Conclusion: Chonghelin M30 treatment of newly diagnosed type 2 diabetic patients can significantly lower blood glucose and blood lipid levels, low incidence of hypoglycemia, no weight gain, good safety, and some patients can be gradually disabled insulin.